drugset / Trial / NCT00417833
Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment
Non-randomizedSingle-groupOpen-label
Summary
Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG). Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.
Timeline
- Start
- 2005-12
- Primary completion
- —
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 2.5 mg | Intravitreal |